Clinical trials: Human Immunodeficiency Virus Type 1
HIV-1-infection
Identification of Barriers and Facilitators of Implementation of the Out-of-Hospital Administration of the Long- Acting Combination Cabotegravir+Rilpivirina.
The study will identify the barriers and facilitators of implementation of the out-of-hospital administration of CAB+RPV LA from the point of view of staff participating in the study.
- Trial name
- NCT06643897
- Testing
- Qualitative Interview
- Where
- 9 sites in Spain
- Volunteers
- 13 people
- Sponsor
- Fundación FLS de Lucha Contra el Sida, las Enfermedades Infecciosas y la Promoción de la Salud y la Ciencia
Neuropathy
Pregabalin Versus Placebo In The Treatment Of Neuropathic Pain Associated With HIV Neuropathy
The purpose of this study is to evaluate the efficacy of pregabalin compared to placebo in reducing neuropathic pain associated with HIV neuropathy.
- Trial name
- NCT01049217
- Testing
- pregabalin
- Where
- 63 sites in United States, Colombia and 7 more
- Volunteers
- 377 people
- Sponsor
- Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
HIV Infections
A Study of Ritonavir-Boosted Invirase (Saquinavir) in Treatment-Naïve HIV-1 Infected Patients
This open-label study will evaluate the safety, pharmacokinetics and antiviral activity of a modified Invirase (saquinavir)/ritonavir regimen in treatment-naïve HIV-1 infected patients.
- Trial name
- NCT01638650
- Testing
- Nucleoside Reverse Transcriptase Inhibitor (NRTIs), ritonavir, saquinavir [Invirase]
- Where
- United Kingdom
- Volunteers
- 23 people
- Sponsor
- Hoffmann-La Roche
Infection, Human Immunodeficiency Virus I, HIV Infection
Observational Study Of A Protease Inhibitor (PI) Containing Regimen In Subjects With PI Mutations Selected During Prior Treatment With GW433908 (Fosamprenavir)
This study will assess the efficacy of subsequent protease inhibitor (PI)-containing therapy in subjects who have acquired HIV-1 protease mutations whilst receiving a GW433908 (fosamprenavir)-containing regimen.
- Trial name
- NCT00242840
- Testing
- No intervention; Observational study
- Where
- 7 sites in United States, Italy
- Volunteers
- 20 people
- Sponsor
- ViiV Healthcare
Chronic HIV Infections
Chidamide in Combination With ART for Reactivation of the Latent HIV-1 Reservoir
HIV replication can be effectively suppressed and acquired immunodeficiency syndrome(AIDS) can be prevented with highly active antiretroviral therapy (HAART).
- Trial name
- NCT02902185
- Testing
- ART plus Chidamide
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Tang-Du Hospital
HIV Infections
Tambua Mapema Plus - to Discover HIV Infection Early and Prevent Onward Transmission
This study will assess the impact of an HIV-1 RNA testing intervention targeting adult patients aged 18-39 years who seek urgent care for symptoms at primary care facilities and meet specific risk criteria for acute HIV…
- Trial name
- TMP (NCT03508908)
- Testing
- HIV-1 RNA testing
- Where
- Kenya
- Volunteers
- 2,887 people
- Sponsor
- University of Oxford
HIV-1
bNAbs and Anti-PD-1 in HIV
Antiretroviral therapy (ART) has significantly extended the life expectancy of people living with HIV-1 (PLWH), but it does not cure the infection.
- Trial name
- IDUNN (NCT07820813)
- Testing
- 3BNC117-LS, 10-1074-LS, Nivolumab
- Volunteers
- 90 people
- Sponsor
- Ole Schmeltz Søgaard
HIV
Viral and Immunologic Factors Contributing to the Lack of HIV Transmission Among Couples in Rakai, Uganda
This study will look at viral and immunologic factors involved in protecting against sexually transmitted HIV infection in couples in which one partner is infected and the other is not.
- Trial name
- NCT00342160
- Where
- Uganda
- Volunteers
- 88 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV-1 Infection
Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide Fixed Dose Combination in Adolescents and Children With Human Immunodeficiency Virus-1
The goals of this clinical study are to learn how Bictegravir/Emtricitabine/Tenofovir Alafenamide fixed dose combination (FDC) interacts with the body, confirm the dose, and also to learn more about the safety and tolerability of…
- Trial name
- NCT02881320
- Testing
- B/F/TAF (Adult Strength), B/F/TAF (Low Dose), B/F/TAF (TOS)
- Where
- 25 sites in United States, South Africa and 2 more
- Volunteers
- 177 people
- Sponsor
- Gilead Sciences
HIV Seronegativity, AIDS Vaccines
HIV-1 Vaccine Test in Uninfected Adult Volunteers
This study will test the safety of an experimental vaccine against HIV and examine whether it induces an immune response to HIV. A vaccine is a substance given to try to create resistance or immunity to a disease or infection.
- Trial name
- NCT00047931
- Testing
- VRC-HIVDNA009-00-VP
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
The Detection of Drug-Resistant HIV-1 in Taiwan
To assess the HIV resistance rate to variable antiretroviral agents in Taiwan, especially in patients with treatment failure, and to know the correlation between the drug resistance pattern and the HIV subtype, we will enroll a…
- Trial name
- NCT00690001
- Where
- Taiwan
- Volunteers
- 150 people
- Sponsor
- National Taiwan University Hospital
HIV Infections
Safety and Immune Response to a Recombinant Adenovirus HIV-1 Vaccine in Healthy Adults
Successful control of the HIV epidemic will require a safe and effective vaccine to be developed. A successful vaccine will need to stimulate a widespread immune response.
- Trial name
- NCT00695877
- Testing
- Ad5.ENVA.48 HIV-1 vaccine
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV
Ibalizumab Plus Optimized Background Regimen in Patient With Multi-Drug Resistant HIV
This Phase 3, single arm, multicenter study will evaluate the safety and effectiveness of ibalizumab in treatment-experienced patients infected with multi-drug resistant HIV-1.
- Trial name
- NCT02475629
- Testing
- ibalizumab, Optimized Background Regimen (OBR)
- Where
- 30 sites in United States, Puerto Rico and 1 more
- Volunteers
- 40 people
- Sponsor
- TaiMed Biologics Inc.
HIV Infection
Partners Demonstration Project of PrEP and ART
The purpose of this protocol is to determine user preferences for antiretroviral therapy (ART) for HIV-1 infected partners and pre-exposure prophylaxis (PrEP) HIV-1 un-infected partners and to optimize targeted delivery and…
- Trial name
- NCT02775929
- Testing
- FTC-TDF PrEP, ART
- Where
- 4 sites in Kenya, Uganda
- Volunteers
- 1,013 people
- Sponsor
- University of Washington
HIV/AIDS, Tuberculosis
Dose Escalation Study to Determine the Pharmacokinetics of Atazanavir Administered With RIfampicin to HIV Positive Adults on sEcond-line ART Regimen With Suppressed HIV-1 Viral Load
The standard treatment for TB consists of rifampicin (RIF) as part of the regimen. However, due to drug-drug interactions (DDI), the bioavailability of PIs is greatly reduced when co-administered with RIF necessitating use of…
- Trial name
- DERIVE (NCT04121195)
- Testing
- Dose escalation
- Where
- Uganda
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- University of Liverpool
HIV
Study to Evaluate the Dosage and Safety of Two Intramuscular Injections of an Investigational Clade B HIV Vaccine
This study aimed to evaluate the safety and reactogenicity of two intramuscular injections of two different dosages of an investigational clade B HIV vaccine.
- Trial name
- NCT01320176
- Testing
- Investigational HIV vaccine dose A, Investigational HIV vaccine dose B
- Where
- Belgium
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
AIDS, Tuberculosis
Pharmacokinetic Study of Super-boosted Lopinavir/Ritonavir Given With Rifampin
The object of this study is to evaluate the pharmacokinetic interactions, short term safety and efficacy of standard dose lopinavir/ritonavir 200mg/50 (two tablets twice daily) given with ritonavir 100 mg three tablets twice…
- Trial name
- NCT01700790
- Testing
- Lopinavir/ritonavir and ritonavir
- Where
- Brazil
- Volunteers
- 9 people
- Sponsor
- University of Miami
HIV Seropositive
Study of Vitamin D Supplementation to Male HIV Sero-positive Patients
The investigators want to investigate if HIV sero-positive males benefit from vitamin D supplementation. The study runs in 16 weeks and the participants are treated with one of three placebo controlled regimes (tablets): 1.
- Trial name
- NCT00990678
- Testing
- Rocaltrol, Vitamin D, Calcium
- Where
- Denmark
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Hvidovre University Hospital
Cytomegalovirus Infections, HIV Infections
A Study of HIV and Cytomegalovirus (CMV) in HIV-Infected Patients
To define relationships between 1) HIV load and risk of CMV disease, 2) CMV load and the risk of developing CMV disease, and 3) CMV load and HIV load.
- Trial name
- NCT00001089
- Where
- 36 sites in United States
- Volunteers
- 400 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
HIV Infections
A Study to Compare the Effectiveness of a Four Drug Anti-HIV Regimen Given Alone or in Combination With GM-CSF or IL-12 to HIV-Positive Patients
The purpose of this study is to examine how the level of HIV is reduced in the blood when anti-HIV therapy is initiated. This study will also evaluate whether adding GM-CSF or IL-12 to the anti-HIV drug regimen will increase the…
- Trial name
- NCT00000896
- Testing
- Indinavir sulfate, Lamivudine/Zidovudine, Hepatitis A Vaccine (Inactivated)
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.